Residency · Residency · Psychiatry
Obstructive Sleep Apnea and Psychiatric Comorbidity
Introduction
Obstructive sleep apnea (OSA) is characterized by repetitive upper airway collapse during sleep, causing intermittent hypoxia, sleep fragmentation, and excessive daytime sleepiness. OSA affects approximately 15-30% of men and 10-15% of women, with prevalence increasing with obesity and age. Its psychiatric significance lies in its bidirectional relationship with depression, anxiety, cognitive impairment, and ADHD, and its capacity to mimic or exacerbate psychiatric disorders.
Pathophysiology
Upper airway collapse during sleep due to reduced pharyngeal muscle tone and anatomical factors. Each apnea (complete airflow cessation for 10+ seconds) or hypopnea (partial reduction with oxygen desaturation or arousal) triggers a brief arousal. Consequences: intermittent hypoxia, sleep fragmentation, sympathetic activation, oxidative stress, and systemic inflammation. Severity measured by the apnea-hypopnea index (AHI): mild (5-14), moderate (15-29), severe (30+)
Risk Factors
Obesity (BMI > 30): strongest modifiable risk factor. Male sex, postmenopausal status in women. Anatomical factors: retrognathia, macroglossia, tonsillar hypertrophy, deviated septum. Alcohol and sedative use (relax pharyngeal muscles) Smoking, nasal congestion. Psychotropic medications: antipsychotics (weight gain), benzodiazepines and opioids (respiratory depression, pharyngeal relaxation)
Clinical Presentation
Nighttime Symptoms
Loud, disruptive snoring (often reported by bed partner) Witnessed apneas or gasping. Restless sleep, frequent awakenings, nocturia.
Daytime Symptoms
Excessive daytime sleepiness (Epworth Sleepiness Scale score > 10) Morning headaches. Difficulty concentrating, memory impairment. Irritability, mood changes. Reduced libido.
Psychiatric Comorbidities
Depression
OSA and depression share overlapping symptoms: fatigue, poor concentration, anhedonia, psychomotor slowing. Meta-analyses show a 2-3x increased risk of depression in OSA patients. CPAP treatment improves depressive symptoms in many patients, suggesting a causal contribution. Always screen for OSA in treatment-resistant depression.
Anxiety
OSA is associated with increased rates of generalized anxiety, panic disorder, and PTSD. Nocturnal awakenings with gasping may be misdiagnosed as nocturnal panic attacks. Claustrophobia related to CPAP can worsen anxiety and reduce adherence.
Cognitive Impairment
Deficits in attention, executive function, memory, and processing speed. Chronic intermittent hypoxia damages hippocampal and prefrontal neurons. May mimic or exacerbate mild cognitive impairment and dementia. CPAP treatment can partially reverse cognitive deficits if initiated early.
ADHD
OSA in children is strongly associated with inattention, hyperactivity, and behavioral problems. Adenotonsillectomy for pediatric OSA can improve ADHD symptoms. Adult ADHD-like symptoms may resolve with OSA treatment.
Psychosis and Bipolar Disorder
Sleep deprivation from untreated OSA can trigger manic episodes and exacerbate psychotic symptoms. Antipsychotic-induced weight gain increases OSA risk, creating a vicious cycle.
Diagnosis
Screening Tools
STOP-BANG Questionnaire: Snoring, Tiredness, Observed apneas, Pressure (hypertension), BMI > 35, Age > 50, Neck circumference > 40 cm, Gender (male); score 3+ indicates high risk. Epworth Sleepiness Scale: measures subjective daytime sleepiness. Berlin Questionnaire.
Diagnostic Testing
In-laboratory polysomnography (PSG): gold standard; records EEG, EMG, EOG, airflow, oximetry, respiratory effort. Home sleep apnea testing (HSAT): portable, less expensive; suitable for patients with high pre-test probability and no significant comorbidities. HSAT may underestimate severity; PSG preferred if clinical suspicion remains high despite negative HSAT.
Treatment
Continuous Positive Airway Pressure (CPAP)
First-line treatment for moderate to severe OSA. Delivers constant positive pressure to splint the airway open. Efficacy depends on adherence: defined as use for 4+ hours per night on 70%+ of nights. Barriers to adherence: mask discomfort, claustrophobia, nasal congestion, noise, partner disturbance.
CPAP Adherence Strategies
Proper mask fitting and trial of multiple mask styles. Heated humidification to reduce nasal dryness. Desensitization therapy for claustrophobia (gradual exposure) Motivational interviewing and patient education. Auto-titrating CPAP (APAP) for pressure comfort optimization.
Other Treatments
Oral appliances (mandibular advancement devices): first-line for mild to moderate OSA or CPAP-intolerant patients. Positional therapy: for position-dependent OSA (lateral sleep position) Weight loss: reduces AHI significantly; bariatric surgery may be curative in morbidly obese patients. Hypoglossal nerve stimulation (Inspire device): for moderate to severe OSA with CPAP intolerance. Surgery: uvulopalatopharyngoplasty (UPPP), maxillomandibular advancement; variable efficacy.
Psychotropic Medications and OSA
Medications That Worsen OSA
| Medication Class | Examples | Mechanism of OSA Worsening | Clinical Recommendation |
|---|---|---|---|
| Benzodiazepines | Diazepam, clonazepam, lorazepam | Reduce pharyngeal tone; blunt arousal response | Avoid or use lowest dose; prefer non-BZD alternatives |
| Opioids | Morphine, oxycodone, methadone | Central respiratory depression; pharyngeal relaxation | Avoid if possible; monitor closely; consider naloxone |
| Antipsychotics (high metabolic risk) | Olanzapine, clozapine, quetiapine | Weight gain exacerbates OSA | Monitor weight/BMI; consider metabolically neutral alternatives |
| Sedating antidepressants | Mirtazapine, trazodone | May worsen respiratory events; weight gain (mirtazapine) | Use cautiously; monitor symptoms |
| Muscle relaxants | Baclofen, cyclobenzaprine | Pharyngeal muscle relaxation | Avoid at bedtime if possible |
Benzodiazepines and opioids: reduce pharyngeal tone and blunt arousal response. Antipsychotics (particularly olanzapine, clozapine): weight gain exacerbates OSA. Sedating antidepressants: mirtazapine, trazodone may worsen respiratory events in some patients.
Medications That May Improve OSA
Limited evidence for any psychotropic specifically improving OSA. Weight loss from stimulants or GLP-1 receptor agonists may indirectly reduce AHI.
Key Clinical Pearls
Screen every psychiatric patient with treatment-resistant depression, unexplained fatigue, or cognitive complaints for OSA. OSA and depression are frequently comorbid; treating OSA can improve depressive symptoms and may reduce antidepressant requirements. CPAP adherence is the primary challenge; address barriers proactively and involve sleep medicine colleagues. Antipsychotic-induced weight gain is a modifiable risk factor for developing or worsening OSA. Children with snoring, behavioral problems, and academic difficulties should be evaluated for OSA before diagnosing ADHD.
References
- Peppard PE, Young T, Barnet JH, et al. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol. 2013;177(9):1006-1014.
- Gupta MA, Simpson FC. Obstructive sleep apnea and psychiatric disorders: a systematic review. J Clin Sleep Med. 2015;11(2):165-175.
- Patil SP, Ayappa IA, Caples SM, et al. Treatment of adult obstructive sleep apnea with positive airway pressure: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2019;15(2):335-343.
- Povitz M, Bolo CE, Heitman SJ, et al. Effect of treatment of obstructive sleep apnea on depressive symptoms: systematic review and meta-analysis. PLoS Med. 2014;11(11):e1001762.